[클리니컬 히스토리] 큐로셀 림카토 허가, '5년 無매출' 극복 시험대

The official approval of Limkato marks a pivotal shift for South Korean biotech, transitioning from R&D to the commercialization of sophisticated CAR-T therapies with localized manufacturing. This milestone validates the domestic GMP infrastructure and integrated supply chains, offering a strategic path for companies to overcome chronic financial deficits through high-value personalized medicine.